Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tracing agent, ultrasound combo helps test cancer therapy's effectiveness

11.01.2007
An inexpensive tracing agent used in combination with ultrasound can pinpoint how effectively drugs targeting pancreatic cancer work, researchers at UT Southwestern Medical Center have demonstrated for the first time.

The study, involving human pancreatic tumor cells implanted in mice, opens a new avenue for real-time imaging of a patient’s response to cancer therapies. It appears in the Jan. 1 issue of the journal Clinical Cancer Research.

The UT Southwestern research team focused on pancreatic cancer because it is one of the deadliest cancers, characterized by extensive local invasion and metastasis to the liver, said Dr. Rolf Brekken, assistant professor of surgery and pharmacology and the study’s senior author. The five-year survival rate ranges from only 1 percent to 4 percent for patients diagnosed with the most severe form of cancer of the pancreas called pancreatic andenocarcinoma.

“The current best therapy — including surgery, radiation and chemotherapy — has done little to alter cancer-related deaths of these patients, emphasizing the need for more effective treatment,” said Dr. Brekken, a researcher at the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research at UT Southwestern.

The research team examined how pancreatic tumor cells respond to an experimental anti-cancer agent that targets vascular endothelial growth factor (VEGF), a protein responsible for triggering the development of blood vessels that deliver nutrients and oxygen to tumors, enabling them to grow and spread. Drugs that target VEGF are in a class called anti-angiogenic agents that are designed to choke tumor growth by reducing the number of blood vessels feeding the cancer.

“In general, it has been difficult to assess whether anti-angiogenic drugs are having an impact on tumors in human patients,” said Dr. Brekken. “The sooner we can measure the effectiveness of the treatment, the earlier we can intervene to change anti-cancer agents if a particular drug has no effect. This could be a lifesaving approach in patients with rapidly fatal disease.”

To find the answer, the UT Southwestern team resorted to an inexpensive and commonly used contrast, or tracing agent, called microbubbles. Each tiny bubble measures about one to two microns in diameter — about a hundredth the width of a human hair — and consists of albumin, sugar and an inert gas. Microbubbles are used routinely in echocardiography, for example, allowing cardiologists to see how efficiently and how much blood the heart pumps.

UT Southwestern researchers linked the microbubbles to a targeting agent that delivered the imaging agent to proteins or protein complexes on the surface of tumor blood vessels. They found that the ultrasound signal from the microbubbles decreased in mice that received therapy. The harmless microbubbles remained in the bloodstream and allowed researchers to use ultrasound to get a crisp picture of what was occurring on blood vessels inside the tumor, Dr. Brekken said.

In one of the studies reported, the researchers observed that blocking VEGF activity achieved a 40-percent reduction in mean tumor size after four treatments over a two-week period, a significant controlling of tumor growth, Dr. Brekken said. Importantly, the reduction in tumor size was predicted by the decrease in signal observed non-invasively with the targeted microbubbles.

“Ultrasound is a safe technology and most physicians have an ultrasound machine in their office,” Dr. Brekken said. “In addition, this monitoring technology would neither require radiation nor the injection of toxic substances for imaging purposes.

“We are the first group to show that this technique can be used to monitor the effectiveness of an anti-cancer agent,” he said.

The monitoring method developed by Dr. Brekken and his colleagues would need to obtain approval from the U.S. Food and Drug Administration before it could be used in humans. Microbubbles will have to be engineered for human patients and these microbubbles will need to be linked to anti-cancer agents using chemicals acceptable to the FDA for use in humans.

The research was supported by a grant from Peregrine Pharmaceuticals Inc, a biopharmaceutical company that has an exclusive license from the University of Texas System for the anti-VEGF agent that Dr. Brekken and other UT Southwestern researchers developed and are testing in several preclinical studies. Dr. Brekken also is a consultant to and has equity interest in the company.

Other UT Southwestern researchers contributing to the study included Juliet Carbon, a senior research associate at the Hamon Center; lead author Dr. Grzegorz “Greg” Korpanty, formerly a researcher at the Hamon Center and now a resident in internal medicine at Mater Misericordiae University Hospital in Dublin, Ireland; and Dr. Jason Fleming, former associate professor of surgery at UT Southwestern and now a surgical oncologist at the University of Texas M.D. Anderson Cancer Center. A researcher from Baylor University Medical Center in Dallas also participated.

Toni Heinzl | EurekAlert!
Further information:
http://www.utsouthwestern.edu

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>